BiotechTube
Oncobit

Oncobit

Lausanne, Switzerland· Est.
oncobit.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Oncobit is a private, commercial-stage diagnostics company based in Lausanne, Switzerland, specializing in liquid biopsy solutions for cancer monitoring. Its core offering is a CE-IVDR-marked digital PCR-based platform and software for detecting and tracking ctDNA, initially focused on melanoma. The company is actively expanding its market presence through strategic partnerships with diagnostic firms like ID Solutions and TrilliumBiO, and is engaged in a major clinical utility study to integrate ctDNA monitoring into routine melanoma follow-up.

Oncology

Technology Platform

Digital PCR (dPCR)-based liquid biopsy platform for detecting and monitoring circulating tumor DNA (ctDNA). Includes proprietary assay kits and analytical software for standardized, sensitive, and quantitative cancer monitoring.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The global shift towards liquid biopsy and personalized cancer care creates a large, growing market.
Strategic partnerships enable rapid geographic expansion (e.g., U.S.
via TrilliumBiO) and technology enhancement without major internal R&D costs.
Demonstrating clinical utility in ongoing real-world studies could drive guideline inclusion and reimbursement.

Risk Factors

Intense competition from larger, well-funded diagnostics companies in the liquid biopsy space.
Clinical adoption and reimbursement depend on successful outcomes from real-world utility studies.
Execution risks associated with managing multiple partnerships and scaling as a small private company.

Competitive Landscape

Oncobit competes in the crowded liquid biopsy market against large public companies (e.g., Guardant Health, Natera) and other specialists. Its differentiation lies in a focused dPCR+software platform for monitoring, CE-IVDR mark, and deep clinical partnerships in dermatology-oncology. It faces competition from both comprehensive NGS panels and other dPCR-based monitoring assays.

More companies in Diagnostics & Precision Medicine →More companies in Switzerland →